Read by QxMD icon Read

Journal of Gastrointestinal Oncology

Romain Cohen, Marine Sroussi, Camilla Pilati, Sidney Houry, Pierre Laurent-Puig, Thierry André
Here we report the case of a 20-year-old patient who was diagnosed in 2002 with a metastatic colorectal cancer (CRC). He achieved a complete response under cetuximab-based therapy and remains without disease recurrence until now while chemotherapy was discontinued in 2009. The tumor exhibited high level of epidermal growth factor receptor ( EGFR ) amplification, no mutation in KRAS , NRAS or BRAF genes and a microsatellite-stable (MSS) phenotype. Intriguingly this young patient was carrying a monoallelic germline mutation of MUTYH that was associated with an inactivation of the second allele by loss of heterozygosity on tumor DNA...
August 2018: Journal of Gastrointestinal Oncology
Sofia Palacio, Terri Pollack, Rachel Silva-Smith, Daniel A Sussman, Peter J Hosein
Pancreatic cancer is projected to become the second leading cause of cancer death in the United States by 2030. Deleterious germline mutations can contribute to pancreatic cancer susceptibility. Herein we report a case of a patient with metastatic pancreatic adenocarcinoma to the lung and liver who was found to have a deleterious germline mutation in RAD51C who had a remarkable response to chemotherapy with FOLFIRINOX, a platinum-containing regimen.
August 2018: Journal of Gastrointestinal Oncology
Jessica D Dahmus, Drew L Kotler, David M Kastenberg, C Andrew Kistler
Colorectal cancer (CRC) is the third most common newly diagnosed cancer in both men and women in the Unites States. Colonoscopy has become increasingly popular in CRC screening and represents the gold standard for detecting and removing pre-cancerous lesions. Although colonoscopy is considered a relatively safe procedure, it is invasive and bowel preparation can be challenging for patients. As interest in the gut microbiome has expanded, there have been new links established between bacteria and the development of CRC...
August 2018: Journal of Gastrointestinal Oncology
Muhammad M Fareed, Lyudmila DeMora, Nestor F Esnaola, Crystal S Denlinger, Andreas Karachristos, Eric E Ross, John Hoffman, Joshua E Meyer
Background: Gallbladder cancer (GBC) and cholangiocarcinoma (CCA) are rare entities with relatively poor prognoses. We compared treatment outcomes of definitive resection with or without neoadjuvant therapy in GBC and CCA patients. Methods: All non-metastatic GBC and CCA patients at a single institution who underwent definitive resection from 1992-2016 were analyzed. We compared overall survival (OS), locoregional failure (LRF) and distant failure (DF) in patients who received neoadjuvant therapy (chemotherapy and/or radiation) versus those who did not receive neoadjuvant treatment...
August 2018: Journal of Gastrointestinal Oncology
Veeravich Jaruvongvanich, Tomoki Sempokuya, Linda Wong
Background: Many staging systems and liver reserve models have been proposed to predict hepatocellular carcinoma (HCC) prognosis. However, there is no consensus as to which model provides the best prognostic value. We aimed to investigate the prognostic role of 8 noninvasive models including the albumin-bilirubin index (ALBI), AST to platelet ratio index (APRI), Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP) system, Child-Pugh (CP) class, Fibrosis-4 (FIB-4) score, model for end-stage liver disease (MELD) score, and platelet-albumin-bilirubin index (PALBI) in patients with HCC...
August 2018: Journal of Gastrointestinal Oncology
Kei Moriya, Tadashi Namisaki, Shinya Sato, Akitoshi Douhara, Masanori Furukawa, Hideto Kawaratani, Kosuke Kaji, Mitsuteru Kitade, Naotaka Shimozato, Yasuhiko Sawada, Kenichiro Seki, Soichiro Saikawa, Hiroaki Takaya, Takemi Akahane, Akira Mitoro, Yasushi Okura, Junichi Yamao, Hitoshi Yoshiji
Background: Even though the Barcelona Clinic Liver Cancer (BCLC) staging system is widely accepted, controversies on the management of hepatocellular carcinoma (HCC) still exist. We evaluated the efficacy of an approach with repeated hepatic arterial infusion chemotherapy (HAIC) given at eight-week intervals for the treatment of advanced HCC. Methods: Of the 66 compensated cirrhotic patients with advanced HCC refractory to transcatheter arterial chemo-embolization (TACE) enrolled in our study, 21 were treated by bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) and the rest by sorafenib...
August 2018: Journal of Gastrointestinal Oncology
Michael Buckstein, Edward Kim, Aaron Fischman, Seth Blacksburg, Marcelo Facciuto, Myron Schwartz, Kenneth Rosenzweig
Background: Transarterial chemoembolization (TACE) is the standard for unresectable Barcelona Clinic Liver Cancer (BCLC) B hepatocellular carcinoma (HCC) patients but is not an ablative therapy. This study explores stereotactic body radiation therapy (SBRT) as an adjuvant or salvage to drug eluting bead (DEB)-TACE. Methods: A retrospective review identified patients receiving SBRT within 2 years following DEB-TACE to a target lesion. Primary outcome was objective response (OR) using modified response evaluation criteria in solid tumors (mRECIST)...
August 2018: Journal of Gastrointestinal Oncology
Seyedeh Saideh Daryabari, Reza Safaralizadeh, Mohammadali Hosseinpourfeizi, Yaghoub Moaddab, Behrooz Shokouhi
Background: Gastric adenocarcinoma is known to be the fourth most common cancer type and the second cause of cancer-related deaths. Movement and invasion of cancer cells is one of the major characteristics of the cancer phenotype that various types of network regulate this. Expression levels of slingshot diphosphatase 1 (SSH1) gene has been modulated in this pathway. SSH1 acts as a dephosphorylation and activator of cofilin that this regulating and activating by SSH1 can play a major role in the mobility and migration of the cell...
August 2018: Journal of Gastrointestinal Oncology
Andrew M Briggler, Rondell P Graham, Gustavo F Westin, Andrew L Folpe, Dawn E Jaroszewski, Scott H Okuno, Thorvardur R Halfdanarson
Background: Our aim was to characterize the clinicopathological features and outcomes of gastrointestinal stromal tumors (GISTs) arising from the esophagus and gastroesophageal junction (GEJ) and describe the survival of patients treated at our institution as well as from a national hospital-based registry. Methods: Twenty-eight cases were identified using the Mayo Clinic Cancer Registry from 1997 to 2016, and 1,010 cases from the National Cancer Database (NCDB) between 2004 and 2014, with analysis of TNM staging, histopathological features, mitotic index, immunohistochemical studies, and KIT mutational analysis...
August 2018: Journal of Gastrointestinal Oncology
Brice Jabo, Matthew J Selleck, John W Morgan, Sharon S Lum, Khaled Bahjri, Mayada Aljehani, Carlos A Garberoglio, Mark E Reeves, Jukes P Namm, Naveenraj L Solomon, Fabrizio Luca, Gary Yang, Maheswari Senthil
Background: Recent randomized controlled trials have failed to show a survival difference between adjuvant chemotherapy (CT) and adjuvant chemoradiotherapy (CRT) in patients with resected gastric cancer (GC). However, a subset of patients with lymph node (LN) positive disease may still benefit from CRT. Additional evidence is needed to help guide physicians in identifying patients in whom CRT should be considered. Our objective was then to compare survival outcomes based on lymph node ratio (LNR) (ratio of metastatic to harvested LNs) for patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma treated with surgery and either CT or CRT...
August 2018: Journal of Gastrointestinal Oncology
Victor Hugo Fonseca de Jesus, Marcos Pedro Guedes Camandaroba, Mauro Daniel Spina Donadio, Audrey Cabral, Thiago Pimentel Muniz, Luciana de Moura Leite, Lucas Ferreira Sant'Ana
Background: FOLFIRINOX stands a major breakthrough in the management of metastatic pancreatic adenocarcinoma (MPA). Nonetheless, significant side-effects have been reported using standard FOLFIRINOX. We aimed to compare survival outcomes, response rates and toxicity of patients treated with standard or modified FOLFIRINOX in MPA. Methods: We included patients aged ≥18 years old, with pathologically confirmed MPA, treated with FOLFIRINOX in the first-line setting...
August 2018: Journal of Gastrointestinal Oncology
Michael Chuong, Shahed N Badiyan, Man Yam, Zuofeng Li, Katja Langen, William Regine, Christopher Morris, James Snider, Minesh Mehta, Soon Huh, Michael Rutenberg, Romaine C Nichols
Background: With an increasing number of proton centers capable of delivering pencil beam scanning (PBS), understanding the dosimetric differences in PBS compared to passively scattered proton therapy (PSPT) for pancreatic cancer is of interest. Methods: Optimized PBS plans were retrospectively generated for 11 patients with locally advanced pancreatic cancer previously treated with PSPT to 59.4 Gy on a prospective trial. The primary tumor was targeted without elective nodal coverage...
August 2018: Journal of Gastrointestinal Oncology
Alexandra E Chambers, Jacob Frick, Natalee Tanner, Richard Gerkin, Madappa Kundranda, Tomislav Dragovich
Background: There are few treatment options in metastatic colorectal cancer (mCRC) after progression on standard chemotherapy. Third and fourth line therapies typically consist of regorafenib or trifluridine-tipiracil, however, clinical benefit of these medications is limited, as progression free survival is approximately 1.9 months for regorafenib (Grothey et al. 2013) and 2.0 months for trifluridine-tipiracil (Mayer et al. 2015). Another choice in this setting may include the re-initiation of previously used chemotherapy, therefore in this study we assessed the efficacy and tolerability of chemotherapy re-challenge...
August 2018: Journal of Gastrointestinal Oncology
Ruud J L F Loffeld, Boris Liberov, Pascale E P Dekkers
Background: Years ago, it was established that removal of adenomas will lead to a lower incidence of colorectal cancer. This study aims to establish the occurrence of colorectal cancer in unselected patients after index colonoscopy with polyp removal. Methods: A prospectively collected dataset on colonoscopy covering 25 consecutive years was used. Patients in who during the index (first) procedure a polyp(s) was removed were included. Excluded were patients with colorectal cancer and patients belonging to Lynch families...
August 2018: Journal of Gastrointestinal Oncology
Whitney Guerrero, Gitonga Munene, Paxton V Dickson, Zachary E Stiles, Johnathan Mays, Andrew M Davidoff, Evan S Glazer, David Shibata, Jeremiah L Deneve
Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) offers a potential cure for peritoneal carcinomatosis (PC), whereas aborted cytoreduction is associated with a poor outcome. We evaluate factors associated with aborted CRS procedures. Methods: An IRB approved retrospective review was performed from 12/2011 to 2/2016. Clinicopathologic variables and outcomes are described. Results: Seventy-four patients underwent attempted CRS/HIPEC which was completed in 51 (69%) and aborted in 23 (31%)...
August 2018: Journal of Gastrointestinal Oncology
Vaidehi Ulaganathan, Mirnalini Kandiah, Zalilah Mohd Shariff
Background: Metabolic syndrome was linked with various chronic diseases, including cancer. The study on the effect of metabolic syndrome on colorectal cancer (CRC) was not conducted in Malaysia. Therefore, this study aims to determine the association between metabolic syndromes and its components with CRC, based on the three established definitions. Methods: A multi-centred matched case control study was conducted in five local hospitals. A total of 140 histologically confirmed CRC cases were matched with 280 cancer free controls...
August 2018: Journal of Gastrointestinal Oncology
John M David, Gillian Gresham, Salma K Jabbour, Matthew Deek, Shant Thomassian, John M Robertson, Neil B Newman, Joseph M Herman, Arsen Osipov, Peyman Kabolizadeh, Richard Tuli
Background: Neoadjuvant chemoradiation (NeoCRT) is standard of care for the treatment of locally advanced rectal cancer (LARC). Contemporary radiation techniques and pre-treatment imaging may impact toxicities and pathologic response (PR). Herein we compare intensity modulated radiotherapy (IMRT) and advanced pre-treatment imaging in the neoadjuvant treatment of LARC and resulting impact on toxicities and pathologic outcomes relative to 3 dimensional conformal radiotherapy (3DCRT). Methods: LARC patients treated at 4 large academic centers in the US from 2007-2016 were reviewed...
August 2018: Journal of Gastrointestinal Oncology
Teresa Martín-Aragón, Javier Serrano, Juana Benedí, Rosa M Meiriño, Pilar García-Alonso, Felipe A Calvo
Background: To evaluate, in a context of innovative multidisciplinary clinical practice, the efficacy of oxaliplatin in adjuvant administration (chemotherapy, CT) in relation to the total administered dose, in terms of prognosis with other clinical and therapeutic factors, in the heterogeneous model of locally advanced rectal cancer (LARC), which is characterized by a risk pattern of dominant systemic progression. Methods: Observational-analytical, retrospective, unicentric, non-randomized study of two cohorts of patients receiving FOLFOX-4 induction CT in neoadjuvancy, radiochemotherapy and surgery, differing in that one cohort did not receive any adjuvant post-surgical treatment and the other one received adjuvant CT with FOLFOX-4 cycles...
August 2018: Journal of Gastrointestinal Oncology
Jaymin Jhaveri, Lael Rayfield, Yuan Liu, Mudit Chowdhary, Sibo Tian, Richard J Cassidy, Theresa Gillespie, Pretesh R Patel, Jerome C Landry, Kirtesh R Patel
Background: This study was designed to investigate the impact of intensity modulated radiation therapy (IMRT) on overall survival (OS) in patients treated with chemoradiation (CRT) for anal cancer (AC). Methods: We performed a case-control, propensity score (PS) matched analysis of the National Cancer Data Base (NCDB) of patients diagnosed with non-metastatic AC from 2004 to 2013. Only patients receiving concurrent CRT were included. Patients were stratified into two groups based on the RT technique: IMRT vs...
August 2018: Journal of Gastrointestinal Oncology
David A Fabrizio, Thomas J George, Richard F Dunne, Garrett Frampton, James Sun, Kyle Gowen, Mark Kennedy, Joel Greenbowe, Alexa B Schrock, Aram F Hezel, Jeffrey S Ross, Phillip J Stephens, Siraj M Ali, Vincent A Miller, Marwan Fakih, Samuel J Klempner
Background: The clinical application of PD1/PD-L1 targeting checkpoint inhibitors in colorectal cancer (CRC) has largely focused on a subset of microsatellite instable (MSI-high) patients. However, the proposed genotype that sensitizes these patients to immunotherapy is not captured by MSI status alone. Estimation of tumor mutational burden (TMB) from comprehensive genomic profiling is validated against whole exome sequencing and linked to checkpoint response in metastatic melanoma, urothelial bladder cancer and non-small cell lung carcinoma...
August 2018: Journal of Gastrointestinal Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"